Glucagon-Like Peptide-1 Agonists Market Poised for Substantial Growth Through 2034
The key Glucagon-Like Peptide-1 Agonists companies in the market include - AstraZeneca, Pfizer, Boehringer Ingelheim, Eli Lilly and Company, and Novo Nordisk, among others.
The latest comprehensive report by DelveInsight delivers detailed insights into the current and forecasted GLP-1 market size across 7MM, covering the period from 2020 to 2034. The glucagon market has witnessed transformative growth in recent years as GLP-1 agonists continue to demonstrate exceptional efficacy in managing type 2 diabetes and weight-related conditions. Key GLP-1 companies driving the growth in this landscape include AstraZeneca, Pfizer, Boehringer Ingelheim, Eli Lilly and Company, and Novo Nordisk, among others.
According to DelveInsight's latest report, ' Glucagon-like Peptide-1 (GLP-1) Agonists Market Size, Target Population, Competitive Landscape & Market Forecast ', the Glucagon-like Peptide-1 (GLP-1) agonists market is projected to expand at a significant CAGR through 2034. The GLP-1 therapeutics market is primarily driven by the rising global diabetes epidemic, with approximately 537 million adults living with diabetes as of 2021. Type 2 diabetes mellitus accounts for over 85% of all diabetes cases, with about 1.4 million new cases diagnosed in the United States alone each year. The condition disproportionately affects older adults, with prevalence exceeding 25% among those over 65 years of age.
The GLP-1 epidemiology landscape continues to evolve as researchers gain deeper insights into the prevalence and distribution of type 2 diabetes and obesity across different demographic groups. DelveInsight's analysis indicates a substantial eligible patient population for GLP-1 therapy, with both diabetes and obesity rates projected to increase throughout the forecast period, further driving demand for effective therapeutic interventions.
Learn more about GLP-1 agonists patient trends by leveraging DelveInsight's expert analysis on GLP-1 epidemiological data
The report also discusses the Glucagon-like Peptide-1 agonists treatment landscape which encompasses various administration options, including injectable and oral formulations, providing patients and healthcare providers with flexible therapeutic approaches.
The current GLP-1 drug market is dominated by several key players and their approved medications. Regulatory bodies have approved multiple GLP-1 receptor agonists, including TRULICITY (Eli Lilly), BYETTA/BYDUREON (AstraZeneca), VICTOZA (Novo Nordisk), OZEMPIC/WEGOVY (Novo Nordisk), and MOUNJARO/ZEPBOUND (Eli Lilly and Company), among others. These medications have demonstrated efficacy in glycemic control and, in some cases, significant weight management benefits, further solidifying their position in the treatment paradigm for metabolic disorders.
The GLP-1 pipeline shows promising results, with several innovative candidates advancing through clinical development. Some of the therapies include orforglipron (Eli Lilly and Company), survodutide (Boehringer Ingelheim), danuglipron (Pfizer), and retatrutide (Eli Lilly and Company), among others. These emerging therapies aim to address current treatment gaps, improve efficacy profiles, and reduce side effects, potentially reshaping the competitive landscape in the coming years.
To uncover key insights into the rapidly growing GLP-1 agonists competitive dynamics and emerging innovations, visit the GLP-1 Market Insights
Recent developments highlight the expanding applications of GLP-1 agonists beyond traditional diabetes management. In July 2024, a significant milestone was reached when the MHRA approved semaglutide to reduce the risk of serious heart problems in obese or overweight adults, making it the first weight-loss drug approved in the UK as a preventative treatment for cardiovascular disease. Additionally, Roche announced promising early weight loss results from Phase I trials of its oral GLP-1 receptor agonist in July 2024.
Further, in November 2024, the FDA approved a generic version of BYETTA (AstraZeneca) by Amneal Pharmaceuticals. This was followed by the approval of a generic version of another GLP-1 receptor agonist, VICTOZA (Novo Nordisk), in December 2024, manufactured by Hikma Pharmaceuticals, suggesting a growing demand in the GLP-1 agonists landscape.
In conclusion, the Glucagon-like Peptide-1 agonists market is poised for significant growth through 2034, driven by the increasing prevalence of type 2 diabetes and obesity worldwide. With a robust pipeline of innovative therapies from leading pharmaceutical companies, the market is expected to witness transformative changes in treatment paradigms.
As new formulations and delivery methods emerge, patient outcomes are likely to improve, potentially expanding the applications of GLP-1 agonists beyond diabetes management. However, challenges such as pricing, reimbursement, and market access will continue to shape the competitive landscape. Stakeholders in the healthcare industry should closely monitor these developments to capitalize on the expanding opportunities in the GLP-1 therapeutics market.
Table of Contents
1.
Key Insights
2.
Report Introduction
3.
Executive Summary of GLP-1 Agonists
4.
Key Events
5.
GLP-1 Agonists Market Overview At A Glance
6.
Background And Overview
7.
Target Population
8.
GLP-1 Agonists Marketed Drugs
9.
GLP-1 Agonists Emerging Drugs
10.
GLP-1 Agonists: The 7MM Analysis
11.
GLP-1 Agonists Unmet Needs
12.
SWOT Analysis
13.
KOL Views
14.
GLP-1 Agonists Market Access and Reimbursement
15.
Appendix
16.
Delveinsight Capabilities
17.
Disclaimer
18.
About DelveInsight
Related Reports
Diabetes Pipeline Insight
Diabetes Pipeline Insight provides comprehensive insights about the Diabetes pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Diabetes companies, including vTv Therapeutics (VTVT), Tonghua Dongbao Pharmaceutical, Eli Lilly and Company (LLY), Celon Pharma (CLN), Sciwind Biosciences, AstraZeneca (AZN), Suzhou Alphamab Co., Ltd., Neurodon, Abarceo Pharma, and Chong Kun Dang Pharmaceutical among others.
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media Contact
Company Name: DelveInsight
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
10 hours ago
- Globe and Mail
Pen Needles Market to Hit USD 3.08 Billion by 2030 with 9.2% CAGR
"Key players in this market are adopting several organic and inorganic growth strategies (such as product launches, agreements, collaborations, acquisitions, and expansions). Prominent players in this market include Embecta Corp. (US), Novo Nordisk A/S (Denmark), Ypsomed AG (Switzerland)" Browse 267 market data Tables and 71 Figures spread through 285 Pages and in-depth TOC on "Pen Needles Market by Type (Standard Pen Needles, Safety Pen Needles), Length (8mm, 5mm), Setting (Home Care Settings), Application (Glucagon-Like Peptide-1 Therapy), Mode of Purchase (Over the Counter Purchase, Online Purchase) - Global Forecast to 2030 The pen needles market valued at US$ 1.69 Billion in 2023, is forecasted to grow at a robust CAGR of 9.2%, reaching US$ 1.81 Billion in 2024 and an impressive US$ 3.08 Billion by 2030. The pen needles market has been segmented based on type, length, application, mode of purchase, setting and region. The key factors driving the market growth of the pen needles market include the rising incidence of chronic diseases, favourable reimbursements in certain countries, and decreasing prices of insulin formulations. Factors that provide opportunities for market players include the growing preference for biosimilar drugs, emerging economies to offer high-growth potential, and rising healthcare expenditure on diabetes. Supportive government regulations, such as rigorous safety standards by the US FDA and favourable reimbursement policies, are also expected to fuel the uptake of technologically advanced products. A combination of these factors is expected to facilitate the increased adoption of pen needles in healthcare systems. Browse in-depth TOC on ' Pen Needles Market' 200 - Tables 80 - Figures 300 - Pages In this report, the pen needles market has been segmented on the basis of type, length, application, mode of purchase, setting and region. The pen needles market is segmented into standard pen needles and safety pen needles on the basis of type. Standard pen needles are budget-friendly needles for insulin delivery, which explains their popularity in low-income markets and among the uninsured. These needles are simple and basic, which makes them easier to manufacture. There is no requirement for ultra-thin design or sophisticated coating that is required for more expensive options. Cost is a major determinant in healthcare in developing nations and low-income brackets. With standard pen needles, accessible options for diabetic patients who need insulin therapy are readily available without worry of financial suffocation. Moreover, for the Grey market practioners in developed countries where people do not have insurance, these needles are a cheap and functional alternative. Thus, standard pen needles are vital because they meet minimum requirements of diabetes control which helps increase the availability of insulin delivery worldwide. The pen needles market is segmented into prescription-based, over the counter (OTC) purchase, online purchase and other modes of purchase on the basis of mode of purchase. Online purchase segment is expected to grow at the highest CAGR during the forecast period of the global pen needles market. As e-commerce grows across the world, the demand for pen needles is also on the rise as new customers are drawn to online shopping. Marketplaces make purchase easier for patients who can now shop for pen needles among other products while sitting in their homes. This is particularly helpful for people with movement disabilities or people living in far flung areas who don't have a ready access to local pharmacies. Businesses engaged in diabetes care and treatment are benefiting enormously as most e-commerce websites offer better rates, promotions, and subscriptions which aid in controlling diabetes. Furthermore, aspects like covert packaging and home delivery make e-commerce users feel more secure and comfortable. The vast variety of products and brands available in these platforms allows customers more purchasing freedom, which aids in increasing their adoption. The pen needles market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa and GCC Countries on the basis of geographic region. North America holds the largest share of the pen needles market in 2024. North America sees one of the maximum diabetes prevalence rates of the world with the U.S and Canada heads in the top of the insulin-dependent population. As per CDC, more than 37 million Americans suffer from diabetes, and approximately 1.6 million have type 1 diabetes. Thus, Canada also bears a huge burden of diabetes cases with an estimated total of 11.7 million that are affected by diabetes or prediabetes. The prevalence of such patients is relatively high, thus increasing demand for pen needles since it's the basic need for managing blood glucose. Pen needles require good infrastructure and wide awareness in place with patients desiring easy-to-handle devices such as pen needles, thereby augmenting the uptake of this equipment. Increased concern regarding proper management of diabetes helps in sustaining the demand in the region. Prominent players in this market include Embecta Corp. (US), Novo Nordisk A/S (Denmark), Ypsomed AG (Switzerland), B. Braun SE (Germany), Owen Mumford (UK), Terumo Corporation (Japan), NIPRO Corporation (Japan), Allison Medical, Inc. (US), AdvaCare Pharma (US), Berpu Medical Technology Co., Ltd. (China), ARKRAY, Inc. (Japan), GlucoRx Limited (UK), HTL-STREFA (Poland), UltiMed, Inc. (US), Hindustan Syringes and Medical Devices (India), Artsana Group (Italy), PromiseMed Medical Devices Inc. (Canada), Montmed, Inc. (Canada), Trividia Health, Inc. (US), VOGT Medical Vertrieb GmbH (Germany), Van Heek Medical (Netherlands), Simple Diagnostics (US), IYON Medical (Turkey), Links Medical Products, Inc. (US), and MHC Medical Products, LLC (US). EMBECTA CORP. (US) One of the main products traded by Embecta in the global market is pen needles. The company operates from a US-based facility, as well as having production plants in Ireland and China. The company's vast range of pen needles, syringes, and safety injection devices is a fundamental factor that helps it withstand competition in global market. Alongside the standard pen needles, the company has a safety pen needle portfolio. The company approaches the growth by both inorganic and organic mechanisms to cement its position in the pen needle market. For instance, on November 2022, Embecta Corporation (US) signed a agreement with Intuity Medical, Inc. (US) under which Embecta sales representatives in the US will promote Intuity Medical's high-tech POGO automatic blood glucose monitoring system to healthcare professionals. NOVO NORDISK A/S (DENMARK) The major source of revenue for the company is its Diabetes and Obesity Care segment. The global diabetes market provides an opportunity for the firm to generate revenues through its Diabetes Care segment. The company obtained approximately 40 million diabetic patients in 2022, from 32 million in Nordisk is well poised in production with ~16 production sites across five regions and a growing product portfolio, including pen needles. The R&D centers of the company are set up in China, Denmark, India, the UK, and the US. Novo Nordisk increased R&D investments from 13.6% in 2022 to 14.0% in 2023. The company also announced that it would be expanding its presence in the pen needles market through a research hub in the greater Boston metro area, which was announced in March 2023. B. BRAUN SE (GERMANY) B. Braun SE is another major player of the pen needle market. In terms of product, the group has a comprehensive presence across geographical boundaries. Also, it has recognition for its branded products, notably Omnican Fine and Omnican Fine Plus injection pen needles. The innovations included in the products such as three facet grinding tip and silicone coating or thin-wall technologies used for injecting pen needles will help the firm obtain a strong presence in branding at the overall markets. The company has a huge geographical presence and subsidiaries in 64 countries. Therefore, it is not dependent on a single market, thus sustaining its leading position. The company intends to focus on new technology and digital transformation for healthcare medical devices. For more information, Inquire Now!
Toronto Sun
17 hours ago
- Toronto Sun
McDonald's shares slump as weight-loss drugs spur rare sell rating
Published Jun 10, 2025 • 1 minute read McDonald's Photo by David Paul Morris / Bloomberg (Bloomberg) — McDonald's Corp. shares slumped on Tuesday after Redburn Atlantic slapped the burger chain with its sole sell rating, saying shifting consumer patterns due to weight-loss drugs and inflation are cause for concern. This advertisement has not loaded yet, but your article continues below. THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY Subscribe now to read the latest news in your city and across Canada. Unlimited online access to articles from across Canada with one account. Get exclusive access to the Toronto Sun ePaper, an electronic replica of the print edition that you can share, download and comment on. Enjoy insights and behind-the-scenes analysis from our award-winning journalists. Support local journalists and the next generation of journalists. Daily puzzles including the New York Times Crossword. SUBSCRIBE TO UNLOCK MORE ARTICLES Subscribe now to read the latest news in your city and across Canada. Unlimited online access to articles from across Canada with one account. Get exclusive access to the Toronto Sun ePaper, an electronic replica of the print edition that you can share, download and comment on. Enjoy insights and behind-the-scenes analysis from our award-winning journalists. Support local journalists and the next generation of journalists. Daily puzzles including the New York Times Crossword. REGISTER / SIGN IN TO UNLOCK MORE ARTICLES Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account. Share your thoughts and join the conversation in the comments. Enjoy additional articles per month. Get email updates from your favourite authors. THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK. Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account Share your thoughts and join the conversation in the comments Enjoy additional articles per month Get email updates from your favourite authors Don't have an account? Create Account Shares of McDonald's fell as much as 1.6% in premarket trading on the downgrade, a two-notch cut from Redburn's previous buy rating. The stock has declined for six straight days, it's longest losing streak in a year, after closing just below a record high in mid-May. As more Americans turn to GLP-1 drugs like Ozempic to lose weight, McDonald's could see as much as a $428 million annual impact to revenue, representing about 1% of system sales, Redburn Atlantic analyst Chris Luyckx wrote. 'A 1% drag today could easily build to 10% or more over time, particularly for brands skewed toward lower-income consumers or group occasions.' Luyckx also cut McDonald's price target to a Street-low $260, implying a nearly 15% decline from where the stock closed on Monday. Other analysts remain largely split on the stock, with 22 buy-equivalent ratings, 18 hold-equivalent ratings and an average price target of $332, according to data compiled by Bloomberg. This advertisement has not loaded yet, but your article continues below. McDonald's US same-stores sales fell 3.6% in the first-quarter of this year, marking the largest decline since 2020 when people were stuck at home during the pandemic. Fast-food restaurants like McDonald's have also seen a decline in traffic in 40 of the past 43 months, according to the analyst. Despite the slump, McDonald's has increased its average transaction amount through pricing, but lower-income consumers are now opting to eat more at home as the price difference between home and restaurant food increases, according to the report. 'While the brand has historically benefited from consumer trade-down during periods of pressure, recent years of outsized menu pricing have created value-perception challenges, contributing to persistent traffic softness,' Luyckx wrote. Still, McDonald's shares have risen 5% so far this year, but without improved value proposition and menu innovation, continued growth may not be sustainable, he added. Toronto Blue Jays World Relationships Editorial Cartoons Olympics
Globe and Mail
20 hours ago
- Globe and Mail
Facial Lines Market Set for Significant Transformation by 2032, Forecasts DelveInsight
"Facial Lines Market" Facial Lines Companies working in the market are Ipsen, Evolus, Inc., and others. (Albany, USA) DelveInsight's ' Facial Lines - Market Insight, Epidemiology, And Market Forecast - 2032 ″ report offers an in-depth understanding of the Facial Lines, historical and forecasted epidemiology as well as the Facial Lines market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. The Facial Lines market is experiencing steady advancements, driven by evolving treatment approaches and research innovations. DelveInsight's latest 7MM report provides comprehensive insights into key epidemiology trends and market dynamics. Some of the key facts of the Facial Lines Market Report: According to DelveInsight, the market for Facial Lines in the 7MM is expected to grow steadily from 2019 to 2032. According to the Global Burden of Disease Study 2019, the global incidence of orofacial clefts decreased from 237,258 cases in 1990 to 192,708 cases in 2019, with an age-standardized rate (ASR) reduction from 3.61 per 100,000 in 1990 to 2.98 per 100,000 in 2019. Ultraviolet (UV) light and sunlight exposure significantly accelerate skin aging, resulting in photoaging, which is responsible for 90% of visible skin changes. The wrinkle scale, rated on a 0-9 scale, is a valuable tool in research for evaluating different types of aesthetic procedures. Emerging drugs for aesthetic treatments include IPN10200, PrabotulinumtoxinA-Xvfs, IncobotulinumtoxinA, and others. Leading companies in the aesthetic and dermatology market include Ipsen, Evolus, Inc., and others. Photoaging continues to be a significant factor in skin damage, driving the development of new treatments in the aesthetics industry. To Know in detail about the Facial Lines market outlook, drug uptake, treatment scenario, and epidemiology trends, Click here: Facial Lines Market Forecast Facial Lines Overview Facial lines, commonly known as wrinkles, are visible creases or folds in the skin that develop due to aging, repetitive facial expressions, sun exposure, and other environmental and genetic factors. These lines can appear on different areas of the face, including the forehead, around the eyes (crow's feet), between the eyebrows (glabellar lines), and around the mouth (nasolabial folds and marionette lines). The primary cause of facial lines is the gradual decline in collagen and elastin production, which leads to reduced skin elasticity and firmness. Additionally, repeated muscle movements, such as frowning, smiling, or squinting, contribute to the formation of dynamic wrinkles, which may become static over time as the skin loses its ability to bounce back. External factors such as prolonged sun exposure, smoking, pollution, and poor skincare habits can accelerate the development of facial lines. While facial lines are a natural part of aging, various treatment options are available to minimize their appearance. These include topical treatments (retinoids, peptides, and hyaluronic acid-based creams), minimally invasive procedures (botulinum toxin injections, dermal fillers, and laser therapy), and more advanced interventions like chemical peels, microneedling, and facelift surgery. With increasing consumer demand for aesthetic procedures and advancements in dermatological treatments, the market for facial line reduction continues to grow, offering both preventive and corrective solutions to individuals seeking youthful, smoother skin. Facial Lines Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Facial Lines Drugs Uptake and Pipeline Development Activities The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Facial Lines market or expected to be launched during the study period. The analysis covers the Facial Lines market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the activities of the facial lines pipeline development. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Facial Lines Market Strengths Growing consumer interest in non-invasive and minimally invasive cosmetic procedures, such as botulinum toxin injections and dermal fillers, is driving market expansion. Increasing social media influence and a focus on youthful appearances further fuel demand. Continuous improvements in anti-aging treatments, including next-generation fillers, laser therapies, and skincare formulations with peptides and hyaluronic acid, enhance treatment efficacy and patient satisfaction. Facial Lines Market Weaknesses Premium aesthetic procedures, such as laser resurfacing and high-end dermal fillers, can be expensive, limiting accessibility for a broader population, particularly in developing regions. Strict regulations on cosmetic injectables and emerging anti-aging treatments, along with concerns about side effects or complications, may hinder market growth and delay product approvals. Scope of the Facial Lines Market Report Study Period: 2019–2032 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Facial Lines Therapies: IPN10200, PrabotulinumtoxinA-Xvfs, IncobotulinumtoxinA, and others. Key Facial Lines Companies: Ipsen, Evolus, Inc., and others. Facial Lines Therapeutic Assessment: Facial Lines currently marketed and Facial Lines emerging therapies Facial Lines Market Dynamics: Facial Lines market drivers and Facial Lines market barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Facial Lines Unmet Needs, KOL's views, Analyst's views, Facial Lines Market Access and Reimbursement To learn more about the key players and advancements in the Facial Lines Treatment Landscape, visit the Facial Lines Market Analysis Report Table of Contents 1. Facial Lines Market Report Introduction 2. Executive Summary for Facial Lines 3. SWOT analysis of Facial Lines 4. Facial Lines Patient Share (%) Overview at a Glance 5. Facial Lines Market Overview at a Glance 6. Facial Lines Disease Background and Overview 7. Facial Lines Epidemiology and Patient Population 8. Country-Specific Patient Population of Facial Lines 9. Facial Lines Current Treatment and Medical Practices 10. Facial Lines Unmet Needs 11. Facial Lines Emerging Therapies 12. Facial Lines Market Outlook 13. Country-Wise Facial Lines Market Analysis (2019–2032) 14. Facial Lines Market Access and Reimbursement of Therapies 15. Facial Lines Market Drivers 16. Facial Lines Market Barriers 17. Facial Lines Appendix 18. Facial Lines Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website:
